健康志愿者中丙型肝炎病毒抗病毒药索磷布韦/维帕他韦与增强及未增强人类免疫缺陷病毒抗逆转录病毒方案的药物相互作用研究
两项1期开放标签随机多剂量交叉研究在237名健康志愿者中评估索磷布韦/维帕他韦与多种抗逆转录病毒方案的药代动力学、安全性和耐受性。除与依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯合用时维帕他韦暴露量约降低50%外,未观察到索磷布韦、GS-331007或维帕他韦具有临床相关差异的药代动力学变化。含阿扎那韦、可比司他、达芦那韦、多替拉韦、埃替拉韦、恩曲他滨、洛匹那韦、拉替拉韦、利匹韦林、利托那韦、替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯的方案可与索磷布韦/维帕他韦合用而无需调整剂量,但不推荐索磷布韦/维帕他韦与含依非韦伦方案合用。
要点
- 237名健康志愿者参与两项1期开放标签随机多剂量交叉研究。
- 索磷布韦/维帕他韦与依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯合用时维帕他韦暴露量约降低50%。
- 索磷布韦/维帕他韦与多种抗逆转录病毒方案合用无需调整剂量,但不推荐与含依非韦伦方案合用。
核心结论
- 索磷布韦/维帕他韦可与含阿扎那韦、可比司他、达芦那韦、多替拉韦、埃替拉韦、恩曲他滨、洛匹那韦、拉替拉韦、利匹韦林、利托那韦、替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯的抗逆转录病毒方案合用而无需调整剂量。
- 由于维帕他韦暴露量约降低50%,不推荐索磷布韦/维帕他韦与含依非韦伦的方案合用。
研究设计与样本
- 两项1期开放标签随机多剂量交叉研究纳入健康志愿者,索磷布韦/维帕他韦与抗逆转录病毒方案单独及联合给药。
- 共入选237名参与者;抗逆转录病毒药物包括阿扎那韦、可比司他、达芦那韦、多替拉韦、依非韦伦、埃替拉韦、恩曲他滨、洛匹那韦、拉替拉韦、利匹韦林、利托那韦、替诺福韦艾拉酚胺和富马酸替诺福韦二吡呋酯。
主要发现
- 除与依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯合用时维帕他韦暴露量约降低50%外,索磷布韦、索磷布韦代谢物GS-331007或维帕他韦的药代动力学未观察到具有临床相关差异的变化。
- 与索磷布韦/维帕他韦合用时,抗逆转录病毒药物的药代动力学未观察到具有临床相关差异的变化。
- 研究治疗耐受良好,包括在评估含富马酸替诺福韦二吡呋酯方案期间未观察到肌酐清除率变化。
关键数值与推荐
- 维帕他韦与依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯合用时暴露量约降低50%。
临床怎么用
- 索磷布韦/维帕他韦与含阿扎那韦、可比司他、达芦那韦、多替拉韦、埃替拉韦、恩曲他滨、洛匹那韦、拉替拉韦、利匹韦林、利托那韦、替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯的方案可合用而无需调整剂量。
- 不推荐索磷布韦/维帕他韦与含依非韦伦的方案合用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combining antiviral regimens in the hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected population can be complex as they share overlapping mechanisms for elimination that may result in drug interactions. The pharmacokinetics, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) with multiple antiretroviral (ARV) regimens were evaluated. METHODS: Healthy volunteers were enrolled into 2 phase 1, open-label, randomized, multiple-dose, cross-over studies. SOF/VEL and ARV regimens were administered alone and in combination; ARVs (and pharmacokinetic enhancers) included atazanavir (ATV), cobicistat (COBI), darunavir (DRV), dolutegravir (DTG), efavirenz (EFV), elvitegravir (EVG), emtricitabine (FTC), lopinavir (LPV), raltegravir (RAL), rilpivirine (RPV), ritonavir (RTV), tenofovir alafenamide (TAF), and tenofovir disoproxil fumarate (TDF). Geometric least squares means ratios (coadministration:alone) and 90% confidence intervals were constructed for area under the plasma concentration-time curve over the dosing interval, maximum concentration, and trough, for all analytes. Safety and tolerability were also evaluated. RESULTS: In total, 237 participants were enrolled. No clinically relevant differences in the pharmacokinetics (PK) of SOF, SOF metabolite GS-331007, or VEL were observed other than an approximate 50% decrease in VEL exposure when administered with EFV/FTC/TDF. No clinically relevant differences in the PK of ARVs were observed when administered with SOF/VEL. Study treatments were well tolerated, including no observed creatinine clearance changes during evaluation of TDF-containing regimens. CONCLUSIONS: SOF/VEL and ARV regimens including ATV, COBI, DRV, DTG, EVG, FTC, LPV, RAL, RPV, RTV, TAF, or TDF may be coadministered without dose adjustment. Use of SOF/VEL with EFV-containing regimens is not recommended due to an approximate 50% reduction in VEL exposure.
引用
- Mogalian E, Stamm LM, Osinusi A, et al. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Clin Infect Dis. 2018. PMID: 29522076. doi:10.1093/cid/ciy201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。